Click for best price
HospitalTreated GramNegative Infections Market Size, Share 2022
Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.
This report contains market size and forecasts of Hospital-Treated Gram-Negative Infections in Global, including the following market information:
Global Hospital-Treated Gram-Negative Infections Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hospital-Treated Gram-Negative Infections market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Klebsiella Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hospital-Treated Gram-Negative Infections include Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d?italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd and Alcon Laboratories. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hospital-Treated Gram-Negative Infections companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital-Treated Gram-Negative Infections Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Type, 2021 (%)
Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others
Global Hospital-Treated Gram-Negative Infections Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Application, 2021 (%)
Public Hospital
Private Hospital
Global Hospital-Treated Gram-Negative Infections Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital-Treated Gram-Negative Infections revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hospital-Treated Gram-Negative Infections revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Pfizer
AstraZeneca
Abbott
Lupin Pharmaceuticals
Istituto lusofarmaco d?italia
Adelco S.A
Zhejiang yuntao biotechnology co., Ltd
Alcon Laboratories
| Report Attributes |
Report Details |
| Report Title |
Hospital-Treated Gram-Negative Infections Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hospital-Treated Gram-Negative Infections Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hospital-Treated Gram-Negative Infections Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hospital-Treated Gram-Negative Infections Overall Market Size
2.1 Global Hospital-Treated Gram-Negative Infections Market Size: 2021 VS 2028
2.2 Global Hospital-Treated Gram-Negative Infections Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hospital-Treated Gram-Negative Infections Players in Global Market
3.2 Top Global Hospital-Treated Gram-Negative Infections Companies Ranked by Revenue
3.3 Global Hospital-Treated Gram-Negative Infections Revenue by Companies
3.4 Top 3 and Top 5 Hospital-Treated Gram-Negative Infections Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hospital-Treated Gram-Negative Infections Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Players in Global Market
3.6.1 List of Global Tier 1 Hospital-Treated Gram-Negative Infections Companies
3.6.2 List of Global Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hospital-Treated Gram-Negative Infections Market Size Markets, 2021 & 2028
4.1.2 Klebsiella
4.1.3 Acinetobacter
4.1.4 Coli
4.1.5 Cepacia
4.1.6 Pseudomonas
4.1.7 Serratia
4.1.8 Enterobacter
4.1.9 Others
4.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
4.2.1 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022
4.2.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028
4.2.3 By Type - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hospital-Treated Gram-Negative Infections Market Size, 2021 & 2028
5.1.2 Public Hospital
5.1.3 Private Hospital
5.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
5.2.1 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022
5.2.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028
5.2.3 By Application - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hospital-Treated Gram-Negative Infections Market Size, 2021 & 2028
6.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
6.2.1 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2022
6.2.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2023-2028
6.2.3 By Region - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hospital-Treated Gram-Negative Infections Revenue, 2017-2028
6.3.2 US Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.3.3 Canada Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.3.4 Mexico Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, 2017-2028
6.4.2 Germany Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.3 France Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.4 U.K. Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.5 Italy Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.6 Russia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.7 Nordic Countries Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.4.8 Benelux Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, 2017-2028
6.5.2 China Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.5.3 Japan Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.5.4 South Korea Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.5.5 Southeast Asia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.5.6 India Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hospital-Treated Gram-Negative Infections Revenue, 2017-2028
6.6.2 Brazil Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.6.3 Argentina Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, 2017-2028
6.7.2 Turkey Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.7.3 Israel Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.7.4 Saudi Arabia Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
6.7.5 UAE Hospital-Treated Gram-Negative Infections Market Size, 2017-2028
7 Players Profiles
7.1 Merck
7.1.1 Merck Corporate Summary
7.1.2 Merck Business Overview
7.1.3 Merck Hospital-Treated Gram-Negative Infections Major Product Offerings
7.1.4 Merck Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.1.5 Merck Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Hospital-Treated Gram-Negative Infections Major Product Offerings
7.2.4 Pfizer Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.2.5 Pfizer Key News
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Hospital-Treated Gram-Negative Infections Major Product Offerings
7.3.4 AstraZeneca Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.3.5 AstraZeneca Key News
7.4 Abbott
7.4.1 Abbott Corporate Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Hospital-Treated Gram-Negative Infections Major Product Offerings
7.4.4 Abbott Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.4.5 Abbott Key News
7.5 Lupin Pharmaceuticals
7.5.1 Lupin Pharmaceuticals Corporate Summary
7.5.2 Lupin Pharmaceuticals Business Overview
7.5.3 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Major Product Offerings
7.5.4 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.5.5 Lupin Pharmaceuticals Key News
7.6 Istituto lusofarmaco d?italia
7.6.1 Istituto lusofarmaco d?italia Corporate Summary
7.6.2 Istituto lusofarmaco d?italia Business Overview
7.6.3 Istituto lusofarmaco d?italia Hospital-Treated Gram-Negative Infections Major Product Offerings
7.6.4 Istituto lusofarmaco d?italia Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.6.5 Istituto lusofarmaco d?italia Key News
7.7 Adelco S.A
7.7.1 Adelco S.A Corporate Summary
7.7.2 Adelco S.A Business Overview
7.7.3 Adelco S.A Hospital-Treated Gram-Negative Infections Major Product Offerings
7.7.4 Adelco S.A Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.7.5 Adelco S.A Key News
7.8 Zhejiang yuntao biotechnology co., Ltd
7.8.1 Zhejiang yuntao biotechnology co., Ltd Corporate Summary
7.8.2 Zhejiang yuntao biotechnology co., Ltd Business Overview
7.8.3 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Major Product Offerings
7.8.4 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.8.5 Zhejiang yuntao biotechnology co., Ltd Key News
7.9 Alcon Laboratories
7.9.1 Alcon Laboratories Corporate Summary
7.9.2 Alcon Laboratories Business Overview
7.9.3 Alcon Laboratories Hospital-Treated Gram-Negative Infections Major Product Offerings
7.9.4 Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue in Global Market (2017-2022)
7.9.5 Alcon Laboratories Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hospital-Treated Gram-Negative Infections Market Opportunities & Trends in Global Market
Table 2. Hospital-Treated Gram-Negative Infections Market Drivers in Global Market
Table 3. Hospital-Treated Gram-Negative Infections Market Restraints in Global Market
Table 4. Key Players of Hospital-Treated Gram-Negative Infections in Global Market
Table 5. Top Hospital-Treated Gram-Negative Infections Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hospital-Treated Gram-Negative Infections Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hospital-Treated Gram-Negative Infections Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hospital-Treated Gram-Negative Infections Product Type
Table 9. List of Global Tier 1 Hospital-Treated Gram-Negative Infections Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hospital-Treated Gram-Negative Infections Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hospital-Treated Gram-Negative Infections Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hospital-Treated Gram-Negative Infections Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hospital-Treated Gram-Negative Infections Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2023-2028
Table 30. Merck Corporate Summary
Table 31. Merck Hospital-Treated Gram-Negative Infections Product Offerings
Table 32. Merck Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Hospital-Treated Gram-Negative Infections Product Offerings
Table 35. Pfizer Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Hospital-Treated Gram-Negative Infections Product Offerings
Table 38. AstraZeneca Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 39. Abbott Corporate Summary
Table 40. Abbott Hospital-Treated Gram-Negative Infections Product Offerings
Table 41. Abbott Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 42. Lupin Pharmaceuticals Corporate Summary
Table 43. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Product Offerings
Table 44. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 45. Istituto lusofarmaco d?italia Corporate Summary
Table 46. Istituto lusofarmaco d?italia Hospital-Treated Gram-Negative Infections Product Offerings
Table 47. Istituto lusofarmaco d?italia Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 48. Adelco S.A Corporate Summary
Table 49. Adelco S.A Hospital-Treated Gram-Negative Infections Product Offerings
Table 50. Adelco S.A Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 51. Zhejiang yuntao biotechnology co., Ltd Corporate Summary
Table 52. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Product Offerings
Table 53. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
Table 54. Alcon Laboratories Corporate Summary
Table 55. Alcon Laboratories Hospital-Treated Gram-Negative Infections Product Offerings
Table 56. Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Hospital-Treated Gram-Negative Infections Segment by Type in 2021
Figure 2. Hospital-Treated Gram-Negative Infections Segment by Application in 2021
Figure 3. Global Hospital-Treated Gram-Negative Infections Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hospital-Treated Gram-Negative Infections Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hospital-Treated Gram-Negative Infections Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hospital-Treated Gram-Negative Infections Revenue in 2021
Figure 8. By Type - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 12. US Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 16. Germany Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 17. France Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 24. China Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 28. India Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 30. Brazil Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue Market Share, 2017-2028
Figure 33. Turkey Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hospital-Treated Gram-Negative Infections Revenue, (US$, Mn), 2017-2028
Figure 37. Merck Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Abbott Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Istituto lusofarmaco d?italia Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Adelco S.A Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
